3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Conditions
Uterine Cervical Neoplasms
7
Uterine Cervical Dysplasia
6
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Squamous Intraepithelial Lesions
1
Precancerous Conditions
1
Papillomavirus Infections
1
Neoplasms by Site
1
Neoplasms
1
Genital Neoplasms, Female
1
Genital Diseases, Female
1
Genital Diseases
1
Female Urogenital Diseases and Pregnancy Complications
1
Acquired Immunodeficiency Syndrome
1
Interventions
Fulvestrant
3
cobimetinib
2
anlotinib
2
Bevacizumab
2
trametinib
1
selinexor
1
ribociclib
1
relacorilant
1
palbociclib
1
osimertinib
1
olaparib
1
niraparib
1
nintedanib
1
exemestane
1
enzalutamide
1
dabrafenib
1
atezolizumab
1
alectinib
1
abemaciclib
1
Watchful Waiting
1
Vemurafenib
1
Transurethral Resection of Prostate
1
Trabectedin
1
Tamoxifen
1
STX-478
1
Pregnancy Tests
1
Pemetrexed
1
Metformin
1
Letrozole
1
Imlunestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
Acetic Acid
×
Gynecologic
×
Clear all
NCT06815939
2026-01-29
OPTICS
DL Analytics
Phase NA
Recruiting
10,000 enrolled